Resilience expands U.S. biologics manufacturing footprint

By The Science Advisory Board staff writers

March 5, 2021 -- Resilience is building its North American presence for biologics manufacturing through the acquisition of two commercial manufacturing facilities, one in Boston and the other in Mississauga, Ontario, Canada.

Founded in 2020, the company is based in La Jolla, CA. It has acquired a facility spanning 310,000 sq ft from Sanofi and a 136,000-sq-ft facility in Ontario through a separate deal. Including the capacity gained through the acquisitions, the company said that it is managing more than 750,000 sq ft.

One of Resilience
One of Resilience's new facilities, located at 500 Soldiers Field road in Boston. Image courtesy of Resilience.

The Ontario facility provides current good manufacturing practice (cGMP) compliant upstream, downstream, and aseptic fill-finish services. The newly acquired Sanofi facility will be built out to facilitate multimodality manufacturing and house state-of-the-art quality laboratories.

Resilience said that it is planning to further beef up its biopharma manufacturing network through the purchase of other sites in the U.S. in 2021.


Copyright © 2021 scienceboard.net


Conferences
Northeast Regional Laboratory Staff and Core Directors (NERLSCD) 2021
November 3-5
Portsmouth, New Hampshire United States
CPhI Worldwide 2021
November 9-11
Milan, Lombardia Italy
Society for Immunotherapy of Cancer (SITC) Annual Meeting
November 10-14
Washington, DC, District of Columbia United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter